EDITORIAL Modernización del uso de la clozapina en Venezuela.

Until few years ago, clozapine (CLZ) was scarcely used in psychiatric patients in Venezuela, even when it was an effective antipsychotic drug in severe mental disorders. This was mainly due to the severe adverse effects (AEs) sometimes occurring during CLZ treatment, and unpredictable drug availability. Even though Venezuela leads South Ameri-can countries in the number of high-quality published studies about the drug’s AEs, local clinicians are still reluctant to its use. Recent knowledge in CLZ pharmacokinetics allows a safer administration. Our research group has promoted an education program about CLZ use in Venezuela, but few colleagues’ have answered our request. We hope this Editorial will improve this attitude, which may lead to improving life quality in psychiatric and neurologi-cal patients with severe disorders.